These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1562758)

  • 1. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
    van Gerven JM; Lemkes HH; van Dijk JG
    J Diabetes Complications; 1992; 6(1):45-8. PubMed ID: 1562758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
    Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA
    Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R
    Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.
    Fabiani F; De Vincentis N; Staffilano A
    Diabete Metab; 1995 Dec; 21(5):360-4. PubMed ID: 8586153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
    Daniele E; Coco MP
    Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients].
    Terranova R; Luca S
    Minerva Med; 1993 Sep; 84(9):461-6. PubMed ID: 8247317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolrestat in the primary prevention of diabetic neuropathy.
    Giugliano D; Acampora R; Marfella R; Di Maro G; De Rosa N; Misso L; Ceriello A; Quatraro A; D'Onofrio F
    Diabetes Care; 1995 Apr; 18(4):536-41. PubMed ID: 7497865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years.
    Didangelos TP; Karamitsos DT; Athyros VG; Kourtoglou GI
    J Diabetes Complications; 1998; 12(4):201-7. PubMed ID: 9647338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in type 2 diabetes.
    Monge L; De Mattei M; Dani F; Sciarretta A; Carta Q
    Diabet Med; 1995 Dec; 12(12):1097-101. PubMed ID: 8750220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM
    Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.
    van Gerven JM; Boot JP; Lemkes HH; van Best JA
    Doc Ophthalmol; 1994; 87(4):355-65. PubMed ID: 7851219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
    Fagius J; Jameson S
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML; McKean ML; Hohman TC; Laver N; Robison WG
    Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.